Biopharmaceutical company Ascentage Pharma said on Wednesday that it has successfully filed its Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for APG-1387 for the treatment of advanced solid tumors and hematologic malignancies.
APG-1387 is a novel small molecule inhibitor of apoptosis (IAP), which was discovered and is being developed by the company. Inhibitors of apoptosis (IAPs) are a group of proteins that act on the intrinsic pathway that blocks programmed cell death or apoptosis. Studies have shown that high expression of IAP protein can promote the occurrence of various malignant tumors, including lung cancer, head and neck cancer, breast cancer, gastrointestinal cancer, melanoma as well as multiple myeloma.
In conjunction, APG-1387, which is being administered to patients once a week, is a dimer inhibitor that binds both IAP protein monomers and dimers, which overcomes the drawbacks of the existing drugs which cannot act on the dimer of the IAP protein. This dual inhibition may improve its effectiveness for more cancers, added the company.
Additionally, APG-1387 has completed Phase 1 dose escalation studies in China and Australia, according to the company.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients